Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol greater than 25 pg/mL.
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Paclitaxel poliglumex (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors CTI BioPharma
Most Recent Events
- 07 Sep 2024 The trial has been completed in Hungary, according to European Clinical Trials Database record.
- 14 Oct 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 14 Oct 2020 Status changed from discontinued to withdrawn prior to enrolment.